LENZ Therapeutics (LENZ) Change in Account Payables (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Change in Account Payables of $6.8 million for Q1 2026, up 977.04% year-over-year from $627830.2 in Q1 2025, and up 4434.62% quarter-over-quarter from -$156000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Change in Account Payables (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Change in Account Payables for 7 consecutive years, with $6.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 977.04% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $7.4 million (up 296.85% YoY), while the FY2025 annual figure was -$90000.0, up 97.9% from the prior year.
- Change in Account Payables climbed to $6.8 million in Q1 2026 per LENZ's latest filing, from -$156000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $6.8 million in Q1 2026 and bottomed at -$2.7 million in Q2 2024.
- Historically, Change in Account Payables has averaged $202529.4 across 5 years, with a median of -$156000.0 in 2025.
- Annual changes were most pronounced in 2023 — Change in Account Payables tumbled 642.86% — and 2026, when it jumped 977.04%.
- LENZ Therapeutics' Change in Account Payables stood at -$1.1 million in 2022, then jumped by 200.65% to $1.1 million in 2023, then gained by 21.32% to $1.3 million in 2024, then slumped by 111.82% to -$156000.0 in 2025, then surged by 4434.62% to $6.8 million in 2026.
- Business Quant data shows LENZ's Change in Account Payables at $6.8 million in Q1 2026, -$156000.0 in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | -4.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.28 Mn |
| Jun 30, 2026 | -4.28 Mn |
| Mar 31, 2026 | 6.76 Mn |
| Mar 31, 2026 | 6.76 Mn |
| Dec 31, 2025 | -156,000.00 |
| Dec 31, 2025 | -156,000.00 |
| Sep 30, 2025 | 1.69 Mn |
| Sep 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | -857,000.00 |
| Jun 30, 2025 | -857,000.00 |
| Mar 31, 2025 | -771,000.00 |
| Mar 31, 2025 | -771,000.00 |
| Dec 31, 2024 | 1.32 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | -1.64 Mn |
| Sep 30, 2024 | -1.64 Mn |
| Jun 30, 2024 | -2.69 Mn |
| Jun 30, 2024 | -2.69 Mn |
| Mar 31, 2024 | -1.27 Mn |
| Mar 31, 2024 | -1.27 Mn |